Teva Pharmaceutical Begins NYSE Ordinary Trading; ADS Program Ends

What Happened
Teva Pharmaceutical Industries Ltd. announced in a Form 8-K (Item 8.01) that on September 14, 2026 the company began trading its ordinary shares on the New York Stock Exchange under the ticker "TEVA," replacing its American depositary shares (ADSs). Also on September 14, 2026 the company's ADS program terminated, with each ADS exchanged for one ordinary share. Teva's ordinary shares continue to trade on the Tel Aviv Stock Exchange under the same symbol, "TEVA."

Key Details

• Event filed on Form 8-K (Item 8.01) and effective September 14, 2026.
• Each ADS was exchanged for one ordinary share (1:1 exchange).
• NYSE ticker remains "TEVA"; Tel Aviv Stock Exchange listing under "TEVA" continues.
• The filing addresses this listing change only; it does not report earnings, executive changes, mergers, or other financial results.

Why It Matters
This change moves U.S. trading from depositary receipts (ADSs) to Teva's underlying ordinary shares, meaning holders of ADSs received ordinary shares on a one-for-one basis. For investors, that affects the form of their holdings (ordinary shares vs. ADSs) and may involve different brokerage custody or settlement procedures. The company's market identifier (ticker "TEVA") remains unchanged on both the NYSE and the Tel Aviv Stock Exchange. For additional details, see Teva’s investor relations at ir.tevapharm.com.